Your browser doesn't support javascript.
loading
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
Herling, Carmen D; Coombes, Kevin R; Benner, Axel; Bloehdorn, Johannes; Barron, Lynn L; Abrams, Zachary B; Majewski, Tadeusz; Bondaruk, Jolanta E; Bahlo, Jasmin; Fischer, Kirsten; Hallek, Michael; Stilgenbauer, Stephan; Czerniak, Bogdan A; Oakes, Christopher C; Ferrajoli, Alessandra; Keating, Michael J; Abruzzo, Lynne V.
Afiliación
  • Herling CD; Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, Cologne, Germany.
  • Coombes KR; Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
  • Benner A; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
  • Bloehdorn J; Internal Medicine III, University Hospital Ulm, Ulm, Germany.
  • Barron LL; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Abrams ZB; Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
  • Majewski T; Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bondaruk JE; Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bahlo J; Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, Cologne, Germany.
  • Fischer K; Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, Cologne, Germany.
  • Hallek M; Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, Cologne, Germany.
  • Stilgenbauer S; Internal Medicine III, University Hospital Ulm, Ulm, Germany.
  • Czerniak BA; Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Oakes CC; Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
  • Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Keating MJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Abruzzo LV; Department of Pathology, The Ohio State University, Columbus, OH, USA. Electronic address: lynne.abruzzo@osumc.edu.
Lancet Oncol ; 20(11): 1576-1586, 2019 11.
Article en En | MEDLINE | ID: mdl-31582354
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vidarabina / Leucemia Linfocítica Crónica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Perfilación de la Expresión Génica / Ciclofosfamida / Transcriptoma / Rituximab / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte / Europa Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vidarabina / Leucemia Linfocítica Crónica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Perfilación de la Expresión Génica / Ciclofosfamida / Transcriptoma / Rituximab / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte / Europa Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Alemania